HIND
Vyome Holdings Delivers Strong Q1 Results with Disciplined Execution and Significant Advancements in Immunoinflammatory and Rare Disease Opportunities
Vyome Holdings recently reported its Q1 2026 financial results, showcasing the company's continued progress in disciplined execution and strategic advancements in immunoinflammatory and rare disease opportunities. According to CEO Venkat Nelabhotla, the quarter represented another important period for the company, with a focus on building a thoughtfully differentiated